Methylenedioxyallylamphetamine

Last updated
MDAL
MDAL.svg
Clinical data
Other namesMDAL; 3,4-Methylenedioxy-N-allylamphetamine
Routes of
administration
Oral [1]
ATC code
  • None
Pharmacokinetic data
Duration of action Unknown [1]
Identifiers
  • N-[1-(2H-1,3-benzodioxol-5-yl)propan-2-yl]prop-2-en-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C13H17NO2
Molar mass 219.284 g·mol−1
3D model (JSmol)
  • C1=C2C(=CC=C1CC(C)NCC=C)OCO2
  • InChI=1S/C13H17NO2/c1-3-6-14-10(2)7-11-4-5-12-13(8-11)16-9-15-12/h3-5,8,10,14H,1,6-7,9H2,2H3 X mark.svgN
  • Key:BMKCDDFQEGYEJC-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Methylenedioxyallylamphetamine (MDAL or 3,4-methylenedioxy-N-allylamphetamine) is a lesser-known drug. [1] [2] [2] It is the N-allyl derivative of 3,4-methylenedioxyamphetamine (MDA). [1] [2]

Contents

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MDAL's minimum dose as 180 mg orally and its duration as unknown. [1] [2] MDAL produces few to no effects on its own, but may enhance the effects of psychedelic drugs like LSD. [1]

Society and culture

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act. [3]

See also

References

  1. 1 2 3 4 5 6 Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628. MDAL entry
  2. 1 2 3 4 Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN   978-0-12-433951-4. Archived from the original on 13 July 2025.
  3. ↑ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.